Seroatlas · Human Serome Atlas

NRROS

Transforming growth factor beta activator LRRC33

Also known as: ELLP3030, GARPL1, LRC33_HUMAN, LRRC33, MGC50789, UNQ3030

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q86YC3
Gene
NRROS
Ensembl
ENSG00000174004
Chromosome
3
Canonical length
692 aa
Protein class
Disease related genes, Predicted membrane proteins

OverviewNCBI Gene

Enables transforming growth factor beta binding activity. Predicted to be involved in several processes, including microglia development; sequestering of TGFbeta in extracellular matrix; and transforming growth factor beta receptor signaling pathway. Located in cell surface. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

692 residues, UniProt reviewed canonical sequence.

>Q86YC3|NRROS
     1  MELLPLWLCL GFHFLTVGWR NRSGTATAAS QGVCKLVGGA ADCRGQSLAS VPSSLPPHAR
    61  MLTLDANPLK TLWNHSLQPY PLLESLSLHS CHLERISRGA FQEQGHLRSL VLGDNCLSEN
   121  YEETAAALHA LPGLRRLDLS GNALTEDMAA LMLQNLSSLR SVSLAGNTIM RLDDSVFEGL
   181  ERLRELDLQR NYIFEIEGGA FDGLAELRHL NLAFNNLPCI VDFGLTRLRV LNVSYNVLEW
   241  FLATGGEAAF ELETLDLSHN QLLFFPLLPQ YSKLRTLLLR DNNMGFYRDL YNTSSPREMV
   301  AQFLLVDGNV TNITTVSLWE EFSSSDLADL RFLDMSQNQF QYLPDGFLRK MPSLSHLNLH
   361  QNCLMTLHIR EHEPPGALTE LDLSHNQLSE LHLAPGLASC LGSLRLFNLS SNQLLGVPPG
   421  LFANARNITT LDMSHNQISL CPLPAASDRV GPPSCVDFRN MASLRSLSLE GCGLGALPDC
   481  PFQGTSLTYL DLSSNWGVLN GSLAPLQDVA PMLQVLSLRN MGLHSSFMAL DFSGFGNLRD
   541  LDLSGNCLTT FPRFGGSLAL ETLDLRRNSL TALPQKAVSE QLSRGLRTIY LSQNPYDCCG
   601  VDGWGALQHG QTVADWAMVT CNLSSKIIRV TELPGGVPRD CKWERLDLGL LYLVLILPSC
   661  LTLLVACTVI VLTFKKPLLQ VIKSRCHWSS VY

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against NRROS can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.3
Highest tissue expression
31 nTPM

Expression across tissuesHPA

Tissue

  • bone marrow: 31 nTPM
  • spleen: 15 nTPM
  • lymph node: 9.9 nTPM
  • placenta: 9.3 nTPM
  • appendix: 8.1 nTPM
  • adipose tissue: 7.5 nTPM

Single-cell type

  • b-cells: 0.3 nCPM
  • monocyte progenitors: 0.3 nCPM
  • nk-cells: 0.3 nCPM
  • thyrotrophs: 0.3 nCPM
  • macrophages: 0.2 nCPM
  • mast cells: 0.2 nCPM

Immune cell

  • basophil: 4.2 nTPM
  • eosinophil: 1.8 nTPM
  • myeloid DC: 1.3 nTPM
  • non-classical monocyte: 1.1 nTPM
  • classical monocyte: 1 nTPM
  • intermediate monocyte: 1 nTPM

Brain region

  • white matter: 9.5 nTPM
  • thalamus: 7.1 nTPM
  • hypothalamus: 6.6 nTPM
  • spinal cord: 6 nTPM
  • pons: 5.8 nTPM
  • medulla oblongata: 5.7 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about NRROS.

Disease | AllUniProt

Conditions NRROS is implicated in, by any mechanism.

  • Seizures, early-onset, with neurodegeneration and brain calcification (SENEBAC) MIM:618875

Disease | GeneticClinVar

12 pathogenic / likely-pathogenic of 136 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

  • Seizures, early-onset, with neurodegeneration and brain calcifications
  • NRROS-related disorder

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.53
gnomAD pLI
0.33
gnomAD missense Z
0.89
DepMap mean gene effect
-0.04
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of NRROS in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads NRROS as an antibody target. Whether an autoantibody or antibody against NRROS could matter depends on whether native NRROS is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

NRROS is annotated at the cell surface, where native NRROS is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label NRROS as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/NRROS. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...